B+
Bull case
20%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
CING
CingulateBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.25
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-04
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+84.3
Score
AI commentary
News tone is constructive following the Phase 3 publication and prior commercial-readiness update, but coverage is sparse. The packet provides no reliable social, options, short-interest, or post-publication price-reaction data, and no validated direct peer set; missing analyst revisions should not be treated as positive evidence.
RankAlpha Sentiment Codex - 2026-08-04
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-07-30eventPublication of Phase 3 CTx-1301 ADHD resultsHigh impact
Company-reported publication of Phase 3 results showed statistically significant improvement versus placebo across all three dose groups, supporting the clinical profile of CTx-1301 and the PTR platform [#PR-EARNINGS-2026-07-30]. The publication is supportive but does not constitute regulatory approval.
2027-08-04catalystFDA review and CMC-response progress for CTx-1301High impact
Cingulate is responding to FDA information requests related to manufacturing and CMC elements of its NDA. Regulatory progress or approval would be material, but timing and outcome remain undisclosed [#SEC-8K-2026-05-14].
2027-08-04catalystCommercial readiness and manufacturing scale-upHigh impact
The company is advancing payer engagement, distribution, manufacturing process validation, and launch infrastructure for CTx-1301 contingent on FDA approval. Management stated resources provide runway into 2027 [#SEC-8K-2026-05-14].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology